Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BNTC Benitec Biopharma

Not Yet Opened 11-04 16:00:00 EST

10.80

-0.12

-1.10%

盘后10.80

+0.000.00%

16:00 EST

High10.91	Low10.50	Vol31.94K
Open10.91	D1 Closing10.92	Amplitude3.75%
Mkt Cap214.00M	Tradable Cap195.52M	Total Shares19.82M
T/O343.59K	T/O Rate0.18%	Tradable Shares18.10M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BNTC","market":"US","secType":"STK","nameCN":"Benitec Biopharma","latestPrice":10.8,"timestamp":1730754000000,"preClose":10.92,"halted":0,"volume":31941,"hourTrading":{"tag":"盘后","latestPrice":10.8,"preClose":10.8,"latestTime":"16:00 EST","volume":23,"amount":248.4,"timestamp":1730754002055},"delay":0,"floatShares":18104054,"shares":19815000,"eps":-5.509605,"marketStatus":"Not Yet Opened","change":-0.12,"latestTime":"11-04 16:00:00 EST","open":10.91,"high":10.91,"low":10.5001,"amount":343588.508458,"amplitude":0.037537,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.509605,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730797200000},"marketStatusCode":0,"adr":1,"adrRate":200,"listingDate":1439870400000,"exchange":"NASDAQ","adjPreClose":10.92,"postHourTrading":{"tag":"盘后","latestPrice":10.8,"preClose":10.8,"latestTime":"16:00 EST","volume":23,"amount":248.4,"timestamp":1730754002055},"volumeRatio":1.629759,"impliedVol":4.2015,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BNTC/tweets","defaultTab":"tweets","newsList":[{"id":"2480300632","title":"Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2480300632","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480300632?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725200,"startTime":"0","endTime":"0","summary":"HAYWARD, Calif., Nov. 04, 2024  -- Benitec Biopharma Inc.  , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference  platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024.Date: November 11, 2024Time: 2:30 PMFormat: Fireside Chat & 1x1 Meetings. The Benitec presentation will also be available via live webcasthere.Please contact your Guggenheim representative to schedule a 1x1 meeting with Benitec management.About Benitec Biopharma Inc.Benitec Biopharma Inc.  is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines tha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wGa4eMZPcYrmKWNEWoa9rw--~B/aD0yNTQ7dz04MDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6420004cb8cbc8cbf0c4b9dec039e88f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wGa4eMZPcYrmKWNEWoa9rw--~B/aD0yNTQ7dz04MDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6420004cb8cbc8cbf0c4b9dec039e88f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/benitec-biopharma-ceo-participate-guggenheim-130000053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","BK4137","BK4139","BNTC"],"gpt_icon":1},{"id":"2480886983","title":"BRIEF-Benitec Biopharma files for mixed shelf of up to $125 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2480886983","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480886983?lang=en_us&edition=fundamental","pubTime":"2024-11-02 06:13","pubTimestamp":1730499211,"startTime":"0","endTime":"0","summary":"Nov 1 (Reuters) - Benitec Biopharma Inc   :   * BENITEC BIOPHARMA INC FILES FOR MIXED SHELF OF UP TO  $125 MILLION - SEC FILINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UP","BNTC","BK4008","BK4139"],"gpt_icon":0},{"id":"2476285196","title":"Benitec Biopharma (BNTC) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2476285196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476285196?lang=en_us&edition=fundamental","pubTime":"2024-10-18 18:36","pubTimestamp":1729247795,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Benitec Biopharma (BNTC – Research Report), with a price t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/benitec-biopharma-bntc-receives-a-buy-from-piper-sandler-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/benitec-biopharma-bntc-receives-a-buy-from-piper-sandler-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC","BK4139"],"gpt_icon":0},{"id":"2476431256","title":"Benitec Biopharma: OPMD Program Continues To Advance With Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2476431256","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476431256?lang=en_us&edition=fundamental","pubTime":"2024-10-18 03:35","pubTimestamp":1729193710,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc.'s BB-301 showed positive interim results in treating OPMD, allowing for higher dosing in 2025 and a potential late-stage trial in 2026.BB-301 demonstrated significant improvements in swallowing function and reduced pharyngeal residue, with no serious adverse events reported in the phase 1b/2a study.Financially, Benitec Biopharma is well-positioned with $50.9 million in cash, sufficient to fund operations through 2025, thanks to a $40 million PIPE financing.Risks include uncertain efficacy and safety of higher BB-301 doses, and regulatory hurdles for advancing to pivotal phase 3 trials.   Solskin Benitec Biopharma Inc.  recently reported positive results from its phase 1b/2a clinical study using BB-301 for the treatment of patients with Oculopharyngeal Muscular Dystrophy [OPMD]. It reported these positive interim results at two time points during 2024 showing initial proof-of-concept that this gene therapy works in being able to treat these patients with this rare","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166158/image_168166158.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166158/image_168166158.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4727454-benitec-biopharma-opmd-program-continues-to-advance-with-catalysts","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","BNTC"],"gpt_icon":0},{"id":"2476692064","title":"Benitec started at outperform by Oppenheimer on gene therapy potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2476692064","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476692064?lang=en_us&edition=fundamental","pubTime":"2024-10-17 03:51","pubTimestamp":1729108281,"startTime":"0","endTime":"0","summary":"peterschreiber.media  Oppenheimer started coverage of Benitec Biopharma (NASDAQ:BNTC) at outperform, citing its gene therapy candidate BB-301 for the treatment of ocular pharyngeal muscular dystrophy,","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1182811515/image_1182811515.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1182811515/image_1182811515.jpg?io=getty-c-w750"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4167071-benitec-started-at-outperform-by-oppenheimer-on-gene-therapy-potential","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["OPY","BNTC"],"gpt_icon":0},{"id":"2475960018","title":"Oppenheimer Initiates Coverage on Benitec Biopharma With Outperform Rating, $35 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2475960018","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475960018?lang=en_us&edition=fundamental","pubTime":"2024-10-16 20:13","pubTimestamp":1729080824,"startTime":"0","endTime":"0","summary":"Price: 10.21, Change: +0.40, Percent Change: +4.08","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","BNTC"],"gpt_icon":0},{"id":"2475960573","title":"Benitec Biopharma Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2475960573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475960573?lang=en_us&edition=fundamental","pubTime":"2024-10-16 20:07","pubTimestamp":1729080446,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241016:nFWN3LS15O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BNTC","BK4139"],"gpt_icon":0},{"id":"2475955833","title":"Benitec Biopharma Initiated at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2475955833","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475955833?lang=en_us&edition=fundamental","pubTime":"2024-10-16 17:22","pubTimestamp":1729070520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BNTC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 16, 2024 05:22 ET (09:22 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPY","BNTC"],"gpt_icon":0},{"id":"2475369859","title":"Benitec Biopharma initiated with an Outperform at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2475369859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475369859?lang=en_us&edition=fundamental","pubTime":"2024-10-16 04:11","pubTimestamp":1729023112,"startTime":"0","endTime":"0","summary":"Oppenheimer initiated coverage of Benitec Biopharma with an Outperform rating and $35 price target Benitec’s proprietary “silence and replace” DNA-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-initiated-with-an-outperform-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-initiated-with-an-outperform-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","BNTC"],"gpt_icon":0},{"id":"2475766406","title":"Benitec Biopharma participates in a conference call with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2475766406","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475766406?lang=en_us&edition=fundamental","pubTime":"2024-10-16 03:45","pubTimestamp":1729021510,"startTime":"0","endTime":"0","summary":"Conference call to be held on October 17 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-participates-in-a-conference-call-with-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-participates-in-a-conference-call-with-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC","BK4139"],"gpt_icon":0},{"id":"2475103955","title":"U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2475103955","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475103955?lang=en_us&edition=fundamental","pubTime":"2024-10-15 15:19","pubTimestamp":1728976777,"startTime":"0","endTime":"0","summary":"Oct 15 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cadence Design Systems, Equity Bancshares and S&P Global, on Tues","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENPH","APA","LU1883866441.USD","VTLE","LBPH","FCX","LU0823414551.USD","LU0889566641.SGD","AFG","PR","VNOM","MUR","STR","LU1582987597.SGD","LU1989764664.SGD","BNTC","EQBK","LU0345780950.USD","LU0985320562.USD","LU1861219969.SGD","MRNA","CDNS","BK4504","BK4213","SNPS","PWR","LU2250418816.HKD","LU0719512351.SGD","LU1267930813.SGD","LU1923622614.USD","LU1815336760.USD","BUSE","BX","DVN","LU0823414478.USD","MSCI","LVS","LU1430597077.USD","LU2355687059.USD","SYRE","KEY","LU1978683503.SGD","IE00BZ1G4Q59.USD","MCO","LU0957791311.USD","XOM","FANG","CHRD","SPGI","IE00BWXC8680.SGD"],"gpt_icon":0},{"id":"2475390712","title":"Benitec Biopharma price target raised to $20 from $13 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2475390712","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475390712?lang=en_us&edition=fundamental","pubTime":"2024-10-15 00:25","pubTimestamp":1728923106,"startTime":"0","endTime":"0","summary":"Leerink raised the firm’s price target on Benitec Biopharma to $20 from $13 and keeps an Outperform rating on the shares following the company’s pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-price-target-raised-to-20-from-13-at-leerink?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-price-target-raised-to-20-from-13-at-leerink?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC"],"gpt_icon":0},{"id":"2475107354","title":"Benitec Biopharma price target lowered to $16 from $18 at JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2475107354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475107354?lang=en_us&edition=fundamental","pubTime":"2024-10-14 18:40","pubTimestamp":1728902421,"startTime":"0","endTime":"0","summary":"JMP Securities analyst Silvan Tuerkcan lowered the firm’s price target on Benitec Biopharma to $16 from $18 and keeps an Outperform rating on the s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-price-target-lowered-to-16-from-18-at-jmp-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-price-target-lowered-to-16-from-18-at-jmp-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC","JMP"],"gpt_icon":0},{"id":"2475356117","title":"Benitec Biopharma Announces Updated Investor Webcast Information","url":"https://stock-news.laohu8.com/highlight/detail?id=2475356117","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475356117?lang=en_us&edition=fundamental","pubTime":"2024-10-14 18:00","pubTimestamp":1728900000,"startTime":"0","endTime":"0","summary":"-Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been rev","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/14/2962404/0/en/Benitec-Biopharma-Announces-Updated-Investor-Webcast-Information.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4121","LU0347712357.USD","LU1165135440.EUR","LU2413666426.HKD","III","BK4588","LU2413666699.HKD","A","LU1543694498.USD","LU2092937221.SGD","BK4585","LU2041044095.USD","BK4134","LU1721428933.USD","BNTC","BK4567"],"gpt_icon":0},{"id":"2475386214","title":"Buy Rating Affirmed for Benitec Biopharma on Strong BB-301 Clinical Results and Positive Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2475386214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475386214?lang=en_us&edition=fundamental","pubTime":"2024-10-14 12:25","pubTimestamp":1728879935,"startTime":"0","endTime":"0","summary":"Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on Benitec Biopharma (BNTC – Research Report), boosting the price target to $18.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-benitec-biopharma-on-strong-bb-301-clinical-results-and-positive-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-benitec-biopharma-on-strong-bb-301-clinical-results-and-positive-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC"],"gpt_icon":0},{"id":"2474889296","title":"Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society","url":"https://stock-news.laohu8.com/highlight/detail?id=2474889296","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474889296?lang=en_us&edition=fundamental","pubTime":"2024-10-12 18:30","pubTimestamp":1728729000,"startTime":"0","endTime":"0","summary":"-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Q","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/12/2962249/0/en/Benitec-Biopharma-Reports-Positive-Data-from-Two-Subjects-Treated-with-Low-Dose-BB-301-in-Phase-1b-2a-Study-Presented-at-29th-Annual-Congress-of-the-World-Muscle-Society.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0347712357.USD","BNTC","BK4097","LU2413666699.HKD","A","BK4121","BK4547","LU2413666426.HKD","BK4167","NH","LU2041044095.USD","LU1543694498.USD","LU1721428933.USD","BK4139","LU1165135440.EUR","LU2092937221.SGD","BK4567","BK4585"],"gpt_icon":0},{"id":"2474025128","title":"BRIEF-Benitec Biopharma Inc Co Entered Into Sales Agreement With Leerink Partners Llc","url":"https://stock-news.laohu8.com/highlight/detail?id=2474025128","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474025128?lang=en_us&edition=fundamental","pubTime":"2024-10-12 05:57","pubTimestamp":1728683860,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc   :   * BENITEC BIOPHARMA INC: CO ENTERED INTO SALES AGREEMENT WITH LEERINK PARTNERS LLC   * BENITEC BIOPHARMA INC: UNDER THE AGREEMENT, CO TO OFFER UP TO $75 MILLION OF CO'S COMMON STOCKSource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIRI","BNTC"],"gpt_icon":0},{"id":"2474284280","title":"Benitec Biopharma Inc: Co Entered Into Sales Agreement With Leerink Partners Llc","url":"https://stock-news.laohu8.com/highlight/detail?id=2474284280","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474284280?lang=en_us&edition=fundamental","pubTime":"2024-10-12 05:18","pubTimestamp":1728681488,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nFWN3LN0W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BNTC","BK4139"],"gpt_icon":0},{"id":"2474028476","title":"Benitec Biopharma Inc: Under the Agreement, Co to Offer up to $75 Mln of Co's Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2474028476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474028476?lang=en_us&edition=fundamental","pubTime":"2024-10-12 05:18","pubTimestamp":1728681488,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nFWN3LN0W1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BNTC"],"gpt_icon":0},{"id":"2474219887","title":"Benitec Biopharma's BB-301: Potential In OPMD But Still Too Early Stages","url":"https://stock-news.laohu8.com/highlight/detail?id=2474219887","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474219887?lang=en_us&edition=fundamental","pubTime":"2024-10-09 13:24","pubTimestamp":1728451445,"startTime":"0","endTime":"0","summary":"Benitec Biopharma develops genetic therapies using its proprietary ddRNAi platform. BB-301, which targets OPMD, has shown promising interim trial results.Despite promising early data, BNTC's valuation","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/646131692/image_646131692.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/646131692/image_646131692.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4725730-benitec-biopharmas-bb-301-potential-in-opmd-but-still-too-early-stages","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BNTC","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.benitec.com","stockEarnings":[{"period":"1week","weight":0.0075},{"period":"1month","weight":0.1392},{"period":"3month","weight":0.2},{"period":"6month","weight":0.25},{"period":"1year","weight":1.7979},{"period":"ytd","weight":2.3437}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.06227},{"month":2,"riseRate":0.555556,"avgChangeRate":0.110444},{"month":3,"riseRate":0.777778,"avgChangeRate":0.056589},{"month":4,"riseRate":0.333333,"avgChangeRate":0.02399},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.070564},{"month":6,"riseRate":0.222222,"avgChangeRate":-0.119694},{"month":7,"riseRate":0.555556,"avgChangeRate":0.075553},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.028649},{"month":9,"riseRate":0.2,"avgChangeRate":-0.125403},{"month":10,"riseRate":0.6,"avgChangeRate":-0.045727},{"month":11,"riseRate":0.4,"avgChangeRate":-0.053949},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.071947}],"exchange":"NASDAQ","name":"Benitec Biopharma","nameEN":"Benitec Biopharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Benitec Biopharma(BNTC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Benitec Biopharma,BNTC,Benitec Biopharma股票,Benitec Biopharma股票老虎,Benitec Biopharma股票老虎国际,Benitec Biopharma行情,Benitec Biopharma股票行情,Benitec Biopharma股价,Benitec Biopharma股市,Benitec Biopharma股票价格,Benitec Biopharma股票交易,Benitec Biopharma股票购买,Benitec Biopharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Benitec Biopharma(BNTC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction